

Recent Advance of Neuronal Cell Antigens and Autoimmune Encephalitis

Ekladios A^{1,2,*}

¹Associate professor of medicine, Faculty of health and medical sciences, University of Western Australia, 35/ Stirling Highway, Perth Western Australia

²Royal Hobart hospital 48 Liverpool Street , Hobart TAZ 7000

Copyright:

©2022 Ekladios A. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.

Citation:

Ekladios A, Recent Advance of Neuronal Cell Antigens and Autoimmune Encephalitis. *Ame J Surg Clin Case Rep.* 2022; 4(7): 1-3

*Corresponding author:

Dr. Adel Ekladios,

1Associate professor of medicine, Faculty of health and medical sciences, University of Western Australia, 35/ Stirling Highway, Perth Western Australia

2Royal Hobart hospital 48 Liverpool Street , Hobart , Tas 7000, Tel: 61499449905,

E-mail: ekladiou@gmail.com

Received: 02 Feb 2022

Accepted: 15 Feb 2022

Published: 21 Feb 2022

J Short Name: AJSCCR

Keywords:

Encephalitis; Immunotherapy; Clinical Manifestation

1. Abstract

Patients with autoimmune encephalitis rarely present to neurology clinic before presenting to memory, seizure, movement disorder, and psychiatry clinics, recent discovery of neuronal surface autoantibodies have shifted the balance towards the diagnosis of autoimmune encephalitis, patients with autoimmune encephalitis used to receive the diagnosis of infectious encephalitis, with poor response to antiseizure, antibacterial and antiviral therapy, autoimmune encephalitis has a fundamental phenotype which is very specific even if serology was negative, early diagnosis is of paramount importance due to starting immunotherapy and avoid mortality and significant morbidity.

1.1. Discussion

Discovery of pathogenic neuroglial surface antibodies has led to discovery of the main clinical manifestation of autoimmune encephalitis and immediate starting of immunotherapy in addition to treating the underlying malignancy [1] although most of autoimmune encephalitis present acutely with a nadir of 10 weeks, others present with a chronic course up to 4 years like Leucine-rich glioma inactivated protein 1 (LG11), antibody Contact -Associated Protein 2 antibody (CASPR2) and Immunoglobulin -Like cell Adhesion Molecule 5 (IGLON5) [2], most forms of autoimmune encephalitis had distinctive clinical manifestation. Which guide clinicians to choose the appropriate panel of autoantibodies, investigation of the causative malignancy and stratify the response to treatment and Prognosis [3]. Chronic progressive forms of autoimmune encephalitis often diagnosed late due to similarities to neurodegenerative diseases [4]. Other differential diagnosis which needed to be ruled out before starting immunotherapy except if the clinical suspicion is very high, included infectious encephalitis,

Hashimoto encephalitis, metabolic encephalitis [5]. Temporal lobe Glioma, Creutzfeldt- Jacob disease and infectious encephalitis, it is currently a standard practice to observe patients with herpes simplex encephalitis for developing autoimmune encephalitis with preemptive treatment with steroid [6]. We will discuss core clinical manifestation of autoimmune encephalitis which should trigger, semi urgent clinical investigation and consider initiating first line immunotherapy after ruling out infectious cause, Psychiatric clinical manifestation which included hallucinations, sleep disorder, aggression is not uncommonly the presenting manifestation of NMDAR-antibody immune encephalitis. Usually, patients with NDMAR antibody encephalitis will not presented to neurologist until other symptoms occur like seizures, involuntary movements, and autonomic symptoms [7].

Patients with Gamma Aminobutyric Acid A Receptors (GABA_AR) antibodies autoimmune encephalitis Have a specific psychiatric phenotype which included catatonia, depression, mania, inappropriate behavior, which makes the diagnosis very difficult in any patient with family history of mental illness. Some patients with systemic lupus can present with the above mentioned manifestations and will be misdiagnosed with autoimmune encephalitis rather than cerebral lupus, low C4 and low to normal C3 support the diagnosis of active cerebral Lupus

2. Seizures

Seizure is a cardinal symptom in autoimmune encephalitis which usually the main reason that patients will be referred to neurologist [8]. Phenotype of seizure can give clue to diagnosis, for example CASPR2 -antibody autoimmune encephalitis is characterized with frequent focal seizures, Patients with LG11- antibody encephalitis has a pathognomonic faciobrachial dystonic seizures, Commonly due dystonic posture of the ipsilateral arm and face, frequent falls

to leg spasm, paroxysmal dizzy spells with negative EEG, temporal lobe seizures, frequent piloerection seizures [9]. Status epileptics are common presentations in GABA_AR and GABA_BR antibody autoimmune encephalitis, the latter is commonly associated with small cell lung cancer, some guidelines advise to investigate. All patients with status epilepticus for autoimmune encephalitis [10]. Myelin Oligodendrocyte Glycoprotein (MOG) antibodies autoimmune encephalitis can present with seizure before other manifestation like optic neuritis and transverse myelitis, seizure usually respond promptly to steroid [11].

Patients with recent diagnosis of epilepsy who have neuronal surface autoantibodies and Autonomic manifestation like tachycardia, Bradycardia, orthostatic hypotension, constipation, diarrhea, steroid responsive seizure, MRI changes in the Limbic system, should be diagnosed and treated as autoimmune encephalitis [11].

3. Movement Disorders

Glycine Receptor (GlyR) and Dipeptidyl Peptidase like Protein 6(DPPX) are characterized by myoclonus and startle syndrome (eye blinking, body spasm in response to unexpected noise, movement or touch) [12] in addition to diarrhea. IgLON5 antibodies due to autoimmune encephalitis is characterized by axial rigidity, supra nuclear gaze palsy and sleep disturbance [13]. CASPR2 antibody autoimmune encephalitis is characterized by episodic or persistent gait ataxia [14], frequent falls are common.

4. Disturbance in Autonomic Nervous System

Dysautonomia is common feature in most of autoimmune encephalitis specially in NMDAR antibody autoimmune encephalitis and can lead to death due to tach or brady arrhythmia and hypotension, few patients need to be treated with pacemaker and vasopressors due to symptomatic bradycardia and hypotension respectively).

5. Cognition

Acute confusion, disorientation are frequent initial manifestation followed by anterograde amnesia in LG11 autoimmune encephalitis, most of limbic autoimmune encephalitis patients experienced marked cognition impairment due to involvement of the Hippocampus, neuropathic pain is common in CASPR2 encephalitis, pruritus is common in Glycine receptor antibody autoimmune encephalitis, pain is less common in LG11 antibody autoimmune encephalitis and usually responds to immunotherapy. Clinicians should have a low threshold to initiate immunotherapy once infectious encephalitis had been ruled out and clinical manifestation is consistent with phenotype syndrome of autoimmune encephalitis. Paired simultaneous autoantibodies from serum and CSF should be ordered, fixed cell-based cell serology should be done first, live cell-based assay should be done only once the former came negative and the clinical suspicious still high. NMDAR serology is more sensitive in CSF than serum, LG11 antibodies are sensitive in serum than CSF.

6. Common Manifestations of Autoimmune Encephalitis

6.1. DPPX Autoimmune Encephalitis

Tremors, Diarrhea, weight loss, myoclonus, and hyperekplexia, normal brain MRI, association with B cell lymphoma, leukemia, gastrointestinal follicular lymphoma.

6.2. IGLONS5

Axial rigidity, Supranuclear palsy, chorea, sleep apnea, disordered REM and NREM sleep, impaired Cognition, bulbar symptoms.

6.3. GLYR Glycin Receptor Antibody

Axial rigidity, myoclonus, limbic encephalitis, impaired REM and NREM sleep.

6.4. MOG (Myelin Oligodendrocyte Glycoprotein Antibody)

young females, optic chiasma involvement, optic neuritis, transverse myelitis, steroid responsive.

6.5. NMDA Receptor Antibody Autoimmune Encephalitis

Manifested initially with psychiatric symptoms, movement disorders, dysautonomia, Ovarian teratoma in 60% of females.

6.6. LG11

Frequent faciobrachial seizures, dystonia of ipsilateral face and arm, spasm in legs causing falls, temporal lobe seizures, piloerection seizures.

6.7. CASPR2

Frequent focal seizures, very rare generalized seizure, neuropathic pain, neuromyotonia, hyperhidrosis, Weight loss, severe insomnia, hallucinations.

6.8. GABA_AR

- Status epilepticus, cortical and subcortical FLAIR signal abnormalities, association with thymoma.
- Seizure response to immunotherapy.

6.9. GABA_BR

Acute limbic encephalitis, rapid progressive dementia, 50% association with small cell lung cancer.

6.10. AMPAR

Manifested with acute confusion, seizures, amnesia, psychiatric symptoms, association with small cell lung cancer, cancer breast, ovary and thymus.

7. Management

CSF usually showed lymphocytic pleocytosis.

- First line immunotherapy includes methyl prednisolone, plasmapheresis and intravenous immunoglobulin is the least effective.
- Second line therapy includes Rituximab, Cyclophosphamide, Mycophenolate, and Azathioprine.
- Third line includes Tocilizumab and Bortezomib.

8. Conclusion

Autoimmune encephalitis is a common disease characterised by highly distinctive features like Seizures, movement disorders, neuropsychiatric symptoms, dysautonomia, and underlying malignancies, and neuronal cell surface autoantibodies, it is a disease not to miss as early diagnosis and initiation of immunotherapy prevent fatality and neurological disability.

References

1. Vincent A, Lang B, Kleopa KA. Autoimmune channelopathy and related neurological disorders. *Neuron*. 2006; 52(1): 1123-38
2. Horresh I, Poliak S, Grant S, Bredt D, Rasband MN, Peles E. Multiple molecular interactions determine the clustering of Casp2 and Kv1 channels in myelinated axons. *J Neurosci*. 2008; 24(52): 14213-22
3. Gastaldi M, Thouin A, Vincent A. Antibody-Medicated autoimmune Encephalopathies and Immunotherapies. 2016; 13(1): 147-62
4. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani, et al. Antibodies to KV1 potassium channel- Complex proteins Leucine rich glioma inactivated 1 protein and cortactin – associated protein -2 in limbic encephalitis, morvans syndrome and acquired neuromyotonia. *Brain* 2010; 133(9): 2734-48
5. Kennedy PGE, Herpes simplex Virus and nervous system. *Postgrad Med J* 1984; 60:253-9
6. Kao Yc, Lin MI, Weng WC, Lee WT. Neuropsychiatric disorders due to limbic encephalitis: immunologic aspect. *Int J Mol. Sci.* 2020; 22(1): 389
7. Asztely F, Kumlien E. The Diagnosis and treatment of limbic Encephalitis. *Acta Neurol Scand*. 2012; 126(6): 365- 75.
8. Schermann H, Ponomareva IV, Maltsev VG, Yakushew KB, Sherman MA. clinical variants of Limbic encephalitis. *SAGE Open Med case Rep*. 2019; 2050313.
9. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LG1 as The antigen in limbic encephalitis previously attributed to potassium channels: a case series, *Lancet Neurol*. 2010; 9(8): 776-85.
10. Leypoldt F, Armangue T, Dalmau J, Autoimmune Encephalopathies. *Ann N Y Acad Sci*. 2015; 1338(1): 94-114.
11. Lancaster E. the diagnosis and treatment of autoimmune encephalitis. *J Clin neurol*. 2016; 12(1): 1-13.
12. Petit-Pedrol M, Armangue T, Peng X. Encephalitis with refractory seizures, status epilepticus and antibodies to the GABAA Receptor: a case series, characterization of the antigen and analysis of the effects of antibodies. *Lancet Neurol*. 2014; 13(3): 276-86
13. Sabater L, Gaig C, Gelpi E. A novel non rapid eye movement and rapid eye movement Parasomnia with sleep breathing disorder associated with antibodies to LHON5: a case series, characterization of the antigen and post mortem study. *Lancet Neurol*. 2014; 13(6): 575-86
14. Kellin CJ, Lennon WA, Aston PA. insights from LG11 and CASPR2 Potassium channel Complex autoantibody subtyping. *JAMA Neurol*. 2013; 70(2): 229-34.